Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello, Rosa Palmiero, Luca Bertero, S. Crasto, Valentina Polo, Roberta Vitaliani, Elena Trincia, Valeria Internò, Camillo Porta, Riccardo Soffietti
Topics & Concepts
RegorafenibTolerabilityMedicineInternal medicineAdverse effectRegimenOncologyProgressive diseaseSurgeryChemotherapyColorectal cancerCancerGlioma Diagnosis and TreatmentBrain Metastases and TreatmentCutaneous Melanoma Detection and Management